This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Arhin, F. F.
Right arrow Articles by Sahm, D. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arhin, F. F.
Right arrow Articles by Sahm, D. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2009, p. 4762-4771, Vol. 53, No. 11
0066-4804/09/$08.00+0     doi:10.1128/AAC.00952-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates{triangledown}

Francis F. Arhin,1* Deborah C. Draghi,2 Chris M. Pillar,2 Thomas R. Parr Jr.,1 Gregory Moeck,1 and Daniel F. Sahm2

The Medicines Company, Saint Laurent, Québec, Canada,1 Eurofins Medinet, Chantilly, Virginia2

Received 9 July 2009/ Returned for modification 20 August 2009/ Accepted 26 August 2009

Oritavancin activity was tested against 15,764 gram-positive isolates collected from 246 hospital centers in 25 countries between 2005 and 2008. Organisms were Staphylococcus aureus (n = 9,075), coagulase-negative staphylococci (n = 1,664), Enterococcus faecalis (n = 1,738), Enterococcus faecium (n = 819), Streptococcus pyogenes (n = 959), Streptococcus agalactiae (n = 415), group C, G, and F streptococci (n = 84), and Streptococcus pneumoniae (n = 1,010). Among the evaluated staphylococci, 56.7% were resistant to oxacillin. The vancomycin resistance rate among enterococci was 21.2%. Penicillin-resistant and -intermediate rates were 14.7% and 21.4%, respectively, among S. pneumoniae isolates. Among nonpneumococcal streptococci, 18.5% were nonsusceptible to erythromycin. Oritavancin showed substantial in vitro activity against all organisms tested, regardless of resistance profile. The maximum oritavancin MIC against all staphylococci tested (n = 10,739) was 4 µg/ml; the MIC90 against S. aureus was 0.12 µg/ml. Against E. faecalis and E. faecium, oritavancin MIC90s were 0.06 and 0.12, respectively. Oritavancin was active against glycopeptide-resistant enterococci, including VanA strains (n = 486), with MIC90s of 0.25 and 1 µg/ml against VanA E. faecium and E. faecalis, respectively. Oritavancin showed potent activity against streptococci (n = 2,468); MIC90s for the different streptococcal species were between 0.008 and 1 µg/ml. These data are consistent with previous studies with respect to resistance rates of gram-positive isolates and demonstrate the spectrum and in vitro activity of oritavancin against a wide variety of contemporary gram-positive pathogens, regardless of resistance to currently used drugs. The data provide a foundation for interpreting oritavancin activity and potential changes in susceptibility over time once oritavancin enters into clinical use.

* Corresponding author. Mailing address: The Medicines Company, 7170 Frederick Banting Street, Second Floor, Saint Laurent, Québec, Canada H4S 2A1. Phone: (514) 332-1008, ext. 1700. Fax: (514) 332-6033. E-mail: francis.arhin{at}themedco.com

{triangledown} Published ahead of print on 8 September 2009.

Antimicrobial Agents and Chemotherapy, November 2009, p. 4762-4771, Vol. 53, No. 11
0066-4804/09/$08.00+0     doi:10.1128/AAC.00952-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»